Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility
American Society of Reproductive Medicine selects findings through scientific peer-review process for presentations at the 75th ASRM Scientific Congress & Expo in October
SALT LAKE CITY, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), announces the presentation of new genetic findings in endometriosis at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo being held October 12-16, 2019 in Philadelphia. The new findings will be presented by Predictive Laboratories’ scientific team. Predictive Technology Group is a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention.
Three scientific presentations (two oral and one poster) highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.
Endometriosis affects more than 10 million women in the United States. It occurs when tissue similar to the lining of the uterus (womb) appears in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others have problems with their menstrual periods, and some have no symptoms at all. Treatment may involve hormonal suppression or surgical destruction of the abnormal tissue.
“We are very pleased with the acceptance of these presentations by ASRM and to be presenting this important data to the thousands of researchers and physicians attending the ASRM meetings,” said Bradley Robinson, CEO of Predictive Technology Group. “Most importantly we look forward to these discoveries being applied in clinical settings to reduce the suffering of millions of women around the world and aiding to eliminate or reduce the related complications of this debilitating disease.
“We look forward to announcing these data following the presentations at ASRM meeting,” he added. “I’m delighted with the commitment of our scientific team and its dedication in continuing to expand the understanding of endometriosis.”
The Company’s population genetics research underlies its novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility currently launched to select collaborators by Predictive Laboratories.
ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
6 Months Old but a Good Read: Founder, Chairman & CEO Of $1.5 Billion NeoGenomics, Dr. Michael Dent, Now Leading HealthLynked To Even Bigger Growth In New Mushrooming $142 Billion Digital Health Market
https://seekingalpha.com/instablog/21922151-bioresearch-alert/5264370-founder-chairman-and-ceo-1_5-billion-neogenomics-dr-michael-dent-now-leading-healthlynked
News Release - HealthLynked Selects PCG Advisory for Investor Relations and Strategic Communications
https://www.globenewswire.com/news-release/2019/08/01/1895510/0/en/HealthLynked-Selects-PCG-Advisory-for-Investor-Relations-and-Strategic-Communications.html
News across my News Feed
8/1/2019 10:52:00: Discovery Gold Corporation (GRN Holding Corporatioin) adds Jeff Sharkey to its Strategic Advisory Board
News
Predictive Laboratories Announces Research Collaboration with the Preeclampsia Foundation
Collaboration to expand the study of genetic factors contributing to preeclampsia and support Predictive Laboratories’ development of personalized products to detect preeclampsia risk before and during pregnancy
SALT LAKE CITY, July 31, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces that its wholly owned subsidiary Predictive Laboratories has entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with preeclampsia. The study will advance the Preeclampsia Foundation’s database of collected preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.
Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, sometimes causing severe adverse maternal and fetal outcomes, including organ failure, massive blood loss, permanent disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually are attributable to preeclampsia. Healthcare providers, even in medically advanced countries, are hampered by imprecise diagnostic tools.
The Preeclampsia Registry, a key program of the Preeclampsia Foundation’s research mission, is a patient registry that collects paired medical information and biological samples. Using established Institutional Review Board-approved protocols, Predictive Laboratories and the Preeclampsia Foundation will request samples from more than 2,500 existing and new registry participants for sequencing analysis. Predictive Laboratories has been granted a period of exclusive access to research data resulting from these new samples enrolled in the Preeclampsia Registry, after which samples and sequencing data will be available to other investigators for future research.
“The Preeclampsia Foundation created an empowered community of patients and experts with a diverse array of resources, support and advocacy to help women have the best possible outcomes from their pregnancies,” said Bradley Robinson, CEO of Predictive Technology Group. “We look forward to enhancing our partnership, helping to grow the Preeclampsia Registry resource and developing innovative and effective products aimed at the early detection and treatment of this devastating medical condition.”
This collaboration complements and extends ongoing preeclampsia research initiatives at Predictive Laboratories. Over 20,000 DNA samples from Predictive's biorepository relating to preeclampsia and associated obstetric syndromes are being analyzed. Predictive Laboratories’ pending patent applications relating to predictive genetic markers of preeclampsia were acquired through its acquisition of Taueret Laboratories, which was completed in March 2019. Prior to acquisition, the Taueret Laboratories team had a long history of collaboration with the Preeclampsia Foundation and invested significant resources towards genotyping and sequencing thousands of samples during discovery work. The combination of knowledge and resources under the Predictive Laboratories subsidiary represents a strong pipeline for developing novel DNA based products.
“We envision a world where preeclampsia no longer threatens the lives of mothers and their babies,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “In addition to a diagnostic test Predictive Laboratories may develop, this infusion of genomic data to our already robust registry accelerates our research agenda and brings us closer to making our vision a reality.”
About the Preeclampsia Foundation
Established in 2000, the Preeclampsia Foundation is the only 501(c)(3) not-for-profit patient advocacy organization representing the 5-8% of pregnant women and their babies who are affected by life-threatening hypertensive disorders of pregnancy, such as preeclampsia, eclampsia, and HELLP syndrome. The Foundation is advised by a medical board comprised of top medical and scientific experts and works collaboratively with many other stakeholders to achieve its mission of improving the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. Additional information is available at Preeclampsia.org and Preeclampsiaregistry.org.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
HealthLynked Announces Participation in the 2019 Florida Medical Association Conference
https://www.globenewswire.com/news-release/2019/07/30/1893591/0/en/HealthLynked-Announces-Participation-in-the-2019-Florida-Medical-Association-Conference-and-Exhibition-in-Orlando-Florida.html
If you want to be incredibly average, diversify.
If you want to be incredibly wealthy, concentrate.
I realize it is a joke. I was just stating that that came across my news feed this morning. I am long....
Just Came Through on Newswire...
NEW: We just learned through a FOIA request that $PRED received a letter from the FDA MONTHS AGO, effectively putting them on notice of potential violations of FDA compliance.
We found ZERO disclosure of this letter to investors (1/3)
https://www.slideshare.net/HindenburgResearch/december-20th-2018-fda-letter-to-predictive-biotech …
6:33 AM - 30 Jul 2019
Growth Hackers...About GRN Funds
GRN Funds is an investment firm established in 2014 by Justin Costello. GRN Funds provides secure banking resources for small to medium businesses and ancillaries. GRN Funds enables businesses to reach larger markets and engage an ecosystem of providers to develop and increase profitability. We proudly serve over 400 businesses across the USA. Our investment strategy focuses on our network of industry leading experts: financial advisers, development experts, growth hackers and data partners with the resources and expertise to rapidly grow our business partners. Our team includes decades of advising, mentoring and investing in multiple verticals touching markets ranging from startup technology, digital services, real estate, retail franchises, analytics and investment banking.
https://en.wikipedia.org/wiki/Growth_hacking
Why Discovery Gold Corp (OTCMKTS:DCGD) Has Been Coming up Aces
https://oracledispatch.com/2019/07/26/why-discovery-gold-corp-otcmktsdcgd-has-been-coming-up-aces/
Justin Costello – CEO of Canna-Exchange (CanEx) and GRN Funds. CanEx brokers bulk cannabis flower and oil to wholesalers & retailers. Mr. Costello (aka “the Fixer”) is a board member of a WA State-chartered bank and assists clients with licensing compliance issues with WA State Liquor & Cannabis Board. Mr. Costello’s expertise includes structuring debt and equity instruments & liquidating distressed assets for the WA State cannabis industry. Justin’s 7 years of industry experience earned him numerous awards and industry accolades. Justin was recently chosen as #1 by MJ Business Magazine’s “Forty under 40” upcoming entrepreneurs for 2018.
Ralph Amato
Ralph Amato · Elevate Acquisitions
For Justin Costello's work with Elevate Acquisitions
Founder Elevate Acquisitions
https://angel.co/justin-costello-1
All the businesses that GRN services are doing business with GRN for the fact that the banks have in essence screwed the Med M industry by not doing business with them. If I was one of those businesses and all of a sudden the banks said, "Okay we will take your business", I would not jump ship and leave GRN.
This just in from cannabis maven Jeff Sharkey
https://floridapolitics.com/archives/301492-last-call-for-7-22-19-a-prime-time-read-of-whats-going-down-in-florida-politics
Let's not forget that Mr Justin's (GRN Funds) $300,000 investment in the shell of Discovery Gold has increased in value to a mere $27,800,000
I seriously doubt that a Hedge Fund manager would let that slip away.
Run some numbers of what the Fund will be worth at some of the predictions that have been posted here. It can be mind boggling that puts a big smile on your face.
I agree with Scotty 100 %
I have ran every scenario of this opportunity through my head. Yes, there are a couple different possibilities. However, each one is a winner.
The Facts remains the same that.
Mr Justin runs GRN Funds.
GRN Holding Corp was created in May.
GRN Funds, LLC bought the clean shell in June.
SEC filings were filed.
Stock started trading.
We have massive gains and when we sell off it roars back.
We had massive support on the bid at 0.20 yesterday.
Here is my post from the 10th when I went to Seattle to sit down with Mr Justin.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149824147
Laws regarding an LLC being a listed public company. The way I understand it, it has to be a C or S Corp.
https://bizfluent.com/info-11386432-can-llc-publicly-traded.html
Again, the link for GRN Holding Corp.
https://opencorporates.com/companies/us_wa/604464402
I thought the card being metallic, looking like a bar of silver made a statement. Showed class. Look at my previous post regarding the meeting.
I did drive over to Seattle and met with Justin for about an hour last Tuesday.
Below is a copy of his business card. It's made out of metal and looks like a silver bar.
While today's action at times was gut retching, it surely should not have surprised us that much. It's been a heck of a run and there are different forms of traders and investors. Some took profits and some got scared out. Oh well...
Here is a list of the DD that I sent out to my fellow investors.
https://grnfunds.com/
https://www.linkedin.com/in/justin-costello-767255159/
https://www.sec.gov/cgi-bin/browse-edgar?company=Discovery+Gold&owner=exclude&action=getcompany
https://www.sec.gov/Archives/edgar/data/1492448/000107997319000381/xslF345X02/ownership.xml
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=dcgd&insttype=&freq=1&show=True&time=19
https://mjbizdaily.com/washington-state-broker-aims-sell-bundle-12-marijuana-retailers/
https://mjbizdaily.com/washingtons-two-top-selling-cannabis-stores-for-sale/
https://mjbizdaily.com/sell-marijuana-business-qa-grn-funds-ceo-justin-costello/
https://mjbizdaily.com/seattle-based-grn-funds-to-provide-cannabis-banking-solutions-in-florida/
https://floridapolitics.com/archives/269356-marijuana-money-new-bank
https://cannabislaw.report/usa-roundup-arkansas-maryland-montana-nevada-washington/
https://x-cannabis.com/businesses/view/406_403/current-c-capital-llc (Click on “Show more” under Executive Summary)
http://www.tmcshows.com/MMBAFL/Agenda.pdf
https://opencorpdata.com/us-wa/604182091
https://mjbizmagazine.com/digital-issues/2017-10-NovDec/18/
https://www.microcapdaily.com/the-explosive-rise-of-reverse-merger-play-discovery-gold-corp-otcmkts-dcgd/124756/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149824147
https://www.bizapedia.com/wa/grn-holding-corporation.html
I Double Agree.
I am a quiet investor when it comes to the boards for various reasons. I do my own DD and on this one I took the time to drive over to Seattle and meet with Mr Justin. As stated in my previous post, I found him to be everything that has been stated regarding him on this board and more.
I have shared this opportunity with many of my fellow investors and we have accumulated a fair amount of shares. I don't share and put my name on the line if I don't feel it is worthy.
There are too many things here that align up. This does not trade like an OTC. I have watched this all day, every day since I got in on July 5th. The trading and patterns show that there is big money behind this with an agenda.
My price target;
$1,000,000,000 / 139,000,000 = $7,20 share
Just saying...
Have a Great Night. I have never slept so well with an investment after meeting Mr Justin
Cultiva is one of the Law Firms for GRN and they do in fact share the same address, I met with Mr Justin Tuesday morning.
Cannabis Attorney for California, Oregon & Washington | Your Business Law Firm
Our clients are dreamers, innovators, risk-takers, and disruptors. As fellow pioneers in this industry we understand your business, legal, and compliance needs. We offer clients unique insights and unparalleled professional solutions to a rapidly changing industry. Our strategic legal counsel lent aid to the groundwork for legalized medicinal cannabis use, as well as its legal protections. We then had several hands in developing the policies and structures allowing the recreational markets to thrive today. Former and current clients rave about our extensive knowledge of cannabis law alongside our genuine desire to help their business thrive. We aren’t just a team of well-versed lawyers—we are true advocates of the industry and culture of cannabis.
Re-Post of my DD From Last Night...
With this board so active I decided to re-post this.
Hello Everyone... My Due Diligence.
I found this opportunity on the evening of July 3rd. Over the holiday I searched everywhere I could possibly imagine for information on Mr Justin and GRN. Picked up some shares Friday morning. Made a call to Mr. Justin. He picked up and we had a short conversation. Realizing I forgot a couple of things I called back and left a message. He called back within a half hour.
Monday morning I picked up some more shares. Called Mr Justin to see if he was available on Tuesday. We arranged for a time to meet. I am about 350 miles away from Seattle so we headed over. I picked up more shares on the dip this morning before our meeting.
Mr Justin and I met for almost an hour at his office. Having kept up with this board and hearing the comments regarding him I had to see for myself. We chuckled together about my due diligence questions. I knew that I was unable to ask the REAL questions that I wanted to ask due to SEC laws. I was interviewing HIM. I found Mr Justin to be everything that has been written here on the board and then some. I told him, "Now I can sleep at night".
Sleeping in tomorrow....Totally confident.
Hello Everyone... My Due Diligence.
I found this opportunity on the evening of July 3rd. Over the holiday I searched everywhere I could possibly imagine for information on Mr Justin and GRN. Picked up some shares Friday morning. Made a call to Mr. Justin. He picked up and we had a short conversation. Realizing I forgot a couple of things I called back and left a message. He called back within a half hour.
Monday morning I picked up some more shares. Called Mr Justin to see if he was available on Tuesday. We arranged for a time to meet. I am about 350 miles away from Seattle so we headed over. I picked up more shares on the dip this morning before our meeting.
Mr Justin and I met for almost an hour at his office. Having kept up with this board and hearing the comments regarding him I had to see for myself. We chuckled together about my due diligence questions. I knew that I was unable to ask the REAL questions that I wanted to ask due to SEC laws. I was interviewing HIM. I found Mr Justin to be everything that has been written here on the board and then some. I told him, "Now I can sleep at night".
Sleeping in tomorrow....Totally confident.
Traveling today for a few days. When I get back, I will see what other information I can get on the battery. Again, I am sleeping well at night. For those that aren't, go to the gym, beat the punching bag, sell your shares and take a tax loss and move on. Period!
Everyone has their opinions. I have been here for 25 days. I have spent many hours with the principles of the company. We were even able to meet Robert.
Dual 275 HP Front Electric Motors
A shot from the front showing the dual side by side Yasa P-750 275 HP Electric Motors.
http://www.yasamotors.com/products/yasa-750/
Dual 275 HP Rear Electric Motors.
The reason the car is taking as long as it has, is they are building it from scratch. Build a little, then figure out how to make the next step work. It is coming along. The shafts are coming in this week. Those are two side by side Yasa P-750 275 HP Electric Motors.
http://www.yasamotors.com/products/yasa-750/
Good Evening,
Yes I do know. I am a shareholder and have been for a long time. I have made the trip to Canada many times to keep myself informed. I arrived here July 23rd and I am still here. You have to understand that this is a development company that has several things going. I will agree that things have not gone as fast as we would like, however I am certain that we will all be very happy. Companies take years and spend millions. The company is moving along nicely. Sit down, have a beer and chill.
I have seen the car and the progress it has made since I have been here. This is a development in progress. I have walked the 48 acre property that was announced Feb. 10, 2016. Too many others to list. All is good.
Sleep well.